Advertisement

Hologic, Inc. HOLX

Set alert

Price alert · HOLX

All alert types
76.01 USD 0.00 0.00%

At close · Apr 7

76.04 +0.03 +0.04%

After hours · Apr 7, 4:00 PM ET

Bid
76.02 × 50
Ask
76.03 × 1
76.01 Day range 76.01

52-week range unavailable

YTD
+2.04%
1 year
+24.06%
Open
76.01
Prev close
76.01
Mkt cap
16.97B
Vol
101.96M
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
76.01
High
76.01
Forward P/E
15.64
Beta
0.70
Short ratio
2.78
Inst. own
96.52%
Dividend
0.00
Ex-div date
Earnings
May 7, 2026
50-d avg
75.31
200-d avg
71.65
1y target
76.67

1M chart

Chart tools
Interval

Signals (5)
NameDateAgo
MACD: Buy SignalMar 24, 20267 months ago
SMA: BullishMar 18, 20267 months ago
SMA: BearishMar 17, 20267 months ago
SMA: BearishMar 11, 20267 months ago
MACD: Sell SignalMar 11, 20267 months ago

Key statistics

Market cap
16.97B
Enterprise value
17.12B
Trailing P/E
31.54
Forward P/E
15.64
PEG ratio
0.00
Price / sales
4.11
Price / book
3.23
EPS (TTM)
2.41
Beta
0.70
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
13.18%
Revenue (TTM)
4.13B
Revenue growth
2.50%
Free cash flow
848.61M
Total cash
2.37B
Total debt
2.52B
Return on equity
10.86%
Shares outstanding
223.24M
Short % of float
3.66%
50-day average
75.31
200-day average
71.65

Analyst view

Consensus: hold

Hold
Price target (mean) 76.67 +0.9% upside
Target (low)
76.00
Target (mean)
76.67
Target (high)
78.00
Ratings (0m) 15 0 buy · 15 hold · 0 sell
  • Strong buy0
  • Buy0
  • Hold15
  • Sell0
  • Strong sell0

Next earnings

May 7, 2026

Expected May 7, 2026. Consensus EPS estimate 1.07.

Earnings history

Financials — quick view

All financials
HOLX Revenue — quarterly 1.05B
2022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 2025
HOLX Net income — quarterly 179.10M
2022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 2025
HOLX EPS — quarterly 0.80
2022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 2025

Earnings

HOLX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
May 7, 2026Mar 1, 20261.09———
Jan 29, 2026Dec 1, 20251.09———
Nov 3, 2025Sep 1, 20251.10———
Jul 30, 2025Jun 1, 20251.05———
May 1, 2025Mar 1, 20251.02———
Feb 5, 2025Dec 1, 20241.02———

Upgrades / downgrades

HOLX analyst upgrades and downgrades
DateFirmActionFromTo
Jan 12, 2026Argus ResearchdownBuyHold
Jan 5, 2026Evercore ISI GroupdownOutperformIn-Line
Nov 11, 2025Morgan StanleymainEqual-WeightEqual-Weight
Oct 23, 2025MizuhodownOutperformNeutral
Oct 22, 2025Raymond JamesdownOutperformMarket Perform
Oct 22, 2025Stephens & Co.downOverweightEqual-Weight

About Hologic, Inc.

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. It also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analysis software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology systems; and breast conserving surgery products. In addition, the company provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system. The company sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States
Website
hologic.com

News

Your note

Sign in to keep a note on HOLX — it syncs with the Stock Master app.

Insider holders

HOLX insider holders
InsiderRelationLatest transactionDateShares held
ANDERSON ERIK SOfficerStock Award(Grant)Nov 10, 202423,621
GRIFFIN JOHN MGeneral CounselStock Award(Grant)Nov 10, 2024183,634
LIDDY ANNE MGeneral CounselStock Award(Grant)Nov 9, 202528,574
MACMILLAN STEPHEN PChief Executive OfficerStock Award(Grant)Nov 9, 20252,577,540
MCBRIDE-WENDELL AMY A.DirectorStock Award(Grant)Feb 25, 202625,784
MITCHELL ESSEX DChief Operating OfficerStock Award(Grant)Nov 9, 202578,952

Institution ownership

HOLX institution ownership
Holder% heldSharesValueReported
Vanguard Group Inc11.69%26,089,4031.98BDec 30, 2025
Blackrock Inc.9.90%22,098,4171.68BDec 30, 2025
State Street Corporation4.42%9,875,663750.65MDec 30, 2025
Manufacturers Life Insurance Co.4.23%9,441,848717.67MDec 30, 2025
HBK Investments L P3.76%8,400,000638.48MDec 30, 2025
T. Rowe Price Investment Management, Inc.2.66%5,932,301450.91MDec 30, 2025

Fund ownership

HOLX fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.14%7,008,595532.72MDec 30, 2025
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.51%5,612,448426.60MDec 30, 2025
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.27%5,057,952384.45MDec 30, 2025
Victory Portfolios-Victory Sycamore Established Value Fund1.80%4,020,000305.56MDec 30, 2025
VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund1.46%3,261,412247.90MDec 30, 2025
-Price (T.Rowe) U.S. Mid-Cap Growth Equity Trust1.32%2,950,500224.27MSep 29, 2025
Advertisement